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The peptide neurokinin A (NKA) is the most active tachykinin in contraction of smooth muscle containing NK-2 receptors. Structure-activity studies proved that the NKA(4-10) fragment constitutes the minimal structural requirement for NK-2 receptor activation. The residues which are important for binding to the NK-2 receptor are Asp4, Phe6 and Metlo-NH,. To define the steric and electrostatic requirement for position six, the following peptides were synthesized by solid phase methodology: [P-X-Phg, Nlelo]NKA(4-10), where X = H, F, C1, I, Br, OH, NH, and NO,, The curve of the control and the p-F-Phe6 peptide are virtually superimposed on each other from the lowest concentrations to the highest concentrations examined. The efficacy, 114.38 f 4.81, did not significantly differ from the control value, i.e. 116.99 f 3.01. The EC,,, values were 126 f 42.78nM and 792 f 18.14nM for the control and for the p-FPhe6 peptide respectively. Introduction of F in the para position of Phe6 had no significant effect on the biological properties of the peptide.
The maximal contraction induced by the p-C1-Phe6 peptide was markedly reduced compared with that of the control. Kp was 2250 f 71nM, indicating a significant reduction in potency. The efficacy, 97.78 f 2.73, of thep-C1-Phe6peptide was also reduced significantly from that, 116.99 f 3.52, of the control peptide. Thus, the peptide appears to be a partial agonist.
The efficacy, 95.77 f2.73, of thep-NH,-Phe6 peptide was significantly lower than that, 116.99 f 3.52, of the controll peptide. The Kp of the p-NH2-Phe6 peptide was 663.1 f 27.54nM. Thus this analogue can also be regarded as a partial agonist.
The dose-response curve of the p-NO,-Phe6 peptide was markedly different than the control curve. Thep-N0,-Phe6 peptide induced a smaller maximal contraction (84.64 f 4.64) than that (116.99 f 3.52) of the control. Even though the efficacy was so considerably reduced, the peptide still retained significant agonist activity. The Kp was 2490 f 74nM.
[Trp6,Nle10]NKA(4-10) had reduced agonist activity; the efficacy, 56.64 f 2.24, was reduced to nearly half that of the control. The Kp, 941 f 30nM, of the partial agonist was significantly different from that of the control. Incorporation of Trp in place of Phe6 resulted partial agonist activity.
The para-F substituted analogue is a full agonist. The efficacy and potency did not signficantly differ from control values. All the other peptides studied differed significantly in potency and efficacy from the para-F substituted and control peptides. The p-NHz-Phe6 peptide was the next most potent peptide but it had significantly reduced biological activity. The other biologically active peptides @XI, p-NO, and Trp6) all closely followed the p-NH, peptide and differed significantly from the control, p-F-and NH,-substituted peptides. The p-CI peptide had reduced potency but the same efficacy as the p-NH,-peptide, but the others @-NO, and Trp6) had both reduced potency and efficacy.
All substituents which had bigger van der Waals volume than that of the F atom had a detrimental effect on biological activity. Neither electron donating nor electron withdrawing properties of substituents correlate with contractile response.
The planarity at position 6 is crucially important for the binding to the receptor. The aromatic ring of the D-Phe analogue falls into the receptor-essential volume, thereby hindering the binding of the peptide to the receptor. Volume mapping of active and inactive peptides defines a rigid binding pocket in the region of receptor which binds the Phe6 residue of analogues of [NlelO]NKA(4-10). The reduction in contractile response to analogues is attributed to perturbance of the steric complementarity with the receptor.
